Drug intelligence / Profile preview

PD-0299685

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PD-0299685 is a small molecule drug developed by Pfizer as an agonist of the alpha2-delta subunit of voltage-dependent calcium channels. This mechanism targets the α2δ subunit implicated in mediating afferent pain fibers and chronic pain signaling. The drug was investigated for several indications including interstitial cystitis/bladder pain syndrome, vasomotor symptoms (such as hot flashes associated with menopause), and insomnia. Clinical trials reached phase II but failed to demonstrate significant efficacy or tolerability advantages over placebo for these conditions[1][2][3][6].

Other names: 61SA6645RLUNII-61SA6645RLUNII61SA6645RLUNII 61SA6645RL3-(Aminomethyl)-5-methyloctanoic acid, (3S,5R)-

Targets

α2δ (Voltage-gated calcium channel alpha-2-delta subunit)

Beyond the preview

Go deeper on PD-0299685.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-0299685.

Explore the full profile